Summary
The provided AI content does not match the full set of claims requiring evaluation against the supplied FDA label excerpts; additionally, many claims are general drug/generic/statements that are not supported or assessable from the supplied AVAPRO fetal toxicity/pregnancy excerpts.
Category Scores
Accurate Statements
AVAPRO (irbesartan) can cause fetal harm and should be discontinued as soon as pregnancy is detected; renin-angiotensin system drugs during 2nd/3rd trimesters reduce fetal renal function and increase fetal/neonatal morbidity and death.
Supported by label excerpts 5.1 Fetal Toxicity and 8.1 Pregnancy (includes instruction to discontinue as soon as pregnancy is detected and describes fetal/neonatal risks during 2nd/3rd trimesters).
Unsupported Statements
Irbesartan is an angiotensin II receptor blocker (ARB).
Not supported by the supplied AVAPRO fetal toxicity/pregnancy excerpts; the provided label material does not address drug class.
Irbesartan is used to treat high blood pressure.
Not supported by the supplied AVAPRO fetal toxicity/pregnancy excerpts; the provided label material does not address indications.
Several pharmaceutical companies manufacture generic versions of irbesartan.
Not supported by the supplied label excerpts.
Generic drug development and sale, including for irbesartan, are driven by patent expirations.
Not supported by the supplied label excerpts.
Once a brand-name drug's patents expire, other companies can produce and market generic versions.
Not supported by the supplied label excerpts.
Generic drugs typically lead to increased competition and lower prices for consumers.
Not supported by the supplied label excerpts.
Generic irbesartan products are required to meet the same standards of quality, safety, and efficacy as the brand-name drug.
Not supported by the supplied label excerpts.
Generic irbesartan contains the same active ingredient as the brand-name drug.
Not supported by the supplied label excerpts.
Generic irbesartan is equivalent in dosage, strength, and route of administration to the brand-name drug.
Not supported by the supplied label excerpts.
Companies that manufacture generic irbesartan often include large generic drug producers.
Not supported by the supplied label excerpts.
Specific generic irbesartan manufacturers can change over time due to market dynamics, acquisitions, and new product launches.
Not supported by the supplied label excerpts.
The United States Food and Drug Administration (FDA) approves and oversees manufacturing of pharmaceutical products, including irbesartan, to ensure they meet strict quality and safety standards.
Not supported by the supplied label excerpts.
The European Medicines Agency (EMA) oversees the manufacturing of pharmaceutical products, including irbesartan, to ensure they meet strict quality and safety standards.
Not supported by the supplied label excerpts.
Common side effects of irbesartan can include dizziness.
Not supported by the supplied label excerpts (which only cover fetal toxicity/pregnancy).
Common side effects of irbesartan can include fatigue.
Not supported by the supplied label excerpts.
Common side effects of irbesartan can include nausea.
Not supported by the supplied label excerpts.
More serious side effects of irbesartan can occur, though they are rare.
Not supported by the supplied label excerpts.
Irbesartan belongs to the drug class angiotensin II receptor blockers (ARBs).
Not supported by the supplied label excerpts.
Other ARBs include losartan, valsartan, olmesartan, and candesartan.
Not supported by the supplied label excerpts.
Other ARBs function similarly to treat hypertension.
Not supported by the supplied label excerpts.
Irbesartan is prescribed for adults to manage high blood pressure.
Not supported by the supplied label excerpts.
Irbesartan is sometimes prescribed for diabetic kidney disease in patients with type 2 diabetes and hypertension.
Not supported by the supplied label excerpts.
Irbesartan is taken orally.
Not supported by the supplied label excerpts.
Irbesartan is typically taken once a day.
Not supported by the supplied label excerpts.
The price of irbesartan varies depending on whether it is brand-name or generic, dosage, quantity purchased, and the pharmacy or insurance plan.
Not supported by the supplied label excerpts.
Generic irbesartan is generally more affordable than the brand-name drug.
Not supported by the supplied label excerpts.
Contradictions
Important Omissions
Because the request included many claims beyond fetal toxicity/pregnancy (e.g., indications, dosing, adverse reactions, administration, drug class), the provided label excerpts are insufficient to validate those claims. A correct label-aligned response would either cite relevant sections (e.g., Indications/Usage, Dosage and Administration, Adverse Reactions) or avoid making unsupported claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only claim demonstrated as label-supported is the fetal toxicity/pregnancy discontinuation guidance. Other claims are not supported by the provided label excerpts and therefore cannot be validated for accuracy from the supplied prescribing information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most provided claims (generic/patent/pricing, adverse effects, dosing, indications, drug class, regulator oversight) are not supported by the supplied FDA label excerpts, which only address fetal toxicity/pregnancy.
Suggested Improvement
Limit statements to information present in the provided label excerpts (fetal toxicity/pregnancy) or supply and cite additional relevant label sections for claims about indications, dosage/administration, adverse reactions, drug class, and contraindications/warnings.